AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+48.83%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.88B
AUM Growth
+$3.88B
(+32%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-3.54%
Top 10 Holdings %
Top 10 Hldgs %
74.76%
Holding
127
New
34
Increased
29
Reduced
17
Closed
18
Top Buys
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$65.1M |
| 2 |
Arrowhead Research
ARWR
|
$57.4M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$29.5M |
| 4 |
Vera Therapeutics
VERA
|
$21.8M |
| 5 |
Solid Biosciences
SLDB
|
$21.2M |
Top Sells
| 1 |
CAVA Group
CAVA
|
$385M |
| 2 |
Cytokinetics
CYTK
|
$49.6M |
| 3 |
argenx
ARGX
|
$44.3M |
| 4 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
$14.8M |
| 5 |
Natera
NTRA
|
$12.5M |
Sector Composition
| 1 | Healthcare | 50.84% |
| 2 | Consumer Discretionary | 48.42% |
| 3 | Technology | 0.53% |
| 4 | Real Estate | 0.1% |
| 5 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CAVA Group
CAVA
$7.83B
| $1.86B | 47.31% | 26,507,990 -5,500,000 | -17% | -$385M |
|
2
Lexicon Pharmaceuticals
LXRX
$400M
| $282M | 7.19% | 117,553,284 | – | – |
|
3
Scholar Rock
SRRK
$3.14B
| $200M | 5.09% | 11,259,438 | – | – |
|
4
Kymera Therapeutics
KYMR
$2.95B
| $122M | 3.1% | 3,027,135 +496,400 | +20% | +$20M |
|
|
5
Arrowhead Research
ARWR
$3.05B
| $86.8M | 2.21% | 3,036,668 +2,008,413 | +195% | +$57.4M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $77.9M | 1.98% | 2,213,188 +75,000 | +4% | +$2.64M |
|
7
Apellis Pharmaceuticals
APLS
$3.48B
| $77.3M | 1.97% | 1,315,282 -106,064 | -7% | -$6.23M |
|
|
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
| $69.7M | 1.77% | 1,415,348 -200,000 | -12% | -$9.84M |
|
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $65.1M | 1.66% | +1,390,477 | New | +$65.1M |
|
|
ONC
10
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $63.3M | 1.61% | 404,782 +302 | +0.1% | +$47.2K |
|
|
SLN
11
Silence Therapeutics
SLN
$227M
| $60M | 1.53% | 2,779,619 -220,381 | -7% | -$4.76M |
|
12
Dyne Therapeutics
DYN
$1.92B
| $43.1M | 1.1% | 1,517,960 +300,000 | +25% | +$8.52M |
|
13
Revolution Medicines
RVMD
$7.1B
| $42.5M | 1.08% | 1,318,649 -377,300 | -22% | -$12.2M |
|
14
Kura Oncology
KURA
$686M
| $41M | 1.04% | 1,919,884 +151,828 | +9% | +$3.24M |
|
15
Neumora Therapeutics
NMRA
$280M
| $40.2M | 1.02% | 2,924,052 +371,350 | +15% | +$5.11M |
|
16
Korro Bio
KRRO
$217M
| $37.7M | 0.96% | 419,226 +621 | +0.1% | +$55.9K |
|
|
17
Cytokinetics
CYTK
$4.23B
| $35.5M | 0.9% | 506,584 -707,700 | -58% | -$49.6M |
|
|
18
Solid Biosciences
SLDB
$427M
| $33.3M | 0.85% | 2,500,000 +1,590,781 | +175% | +$21.2M |
|
|
IGMS
19
DELISTED
IGM Biosciences
IGMS
| $29.7M | 0.76% | 3,080,422 -20,000 | -0.6% | -$193K |
|
|
20
Madrigal Pharmaceuticals
MDGL
$9.76B
| $29.5M | 0.75% | +110,507 | New | +$29.5M |
|
|
CBIO
21
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $25.8M | 0.66% | 8,589,064 | – | – |
|
22
Wave Life Sciences
WVE
$1.53B
| $25M | 0.64% | 4,051,400 +1,044,000 | +35% | +$6.44M |
|
23
Prothena Corp
PRTA
$441M
| $24.8M | 0.63% | 1,001,360 +500,000 | +100% | +$12.4M |
|
|
24
Vera Therapeutics
VERA
$1.38B
| $21.8M | 0.56% | +506,019 | New | +$21.8M |
|
25
Viking Therapeutics
VKTX
$3.04B
| $20.8M | 0.53% | +253,863 | New | +$20.8M |
|